Paul Willems

Paul Willems is a seasoned pharmaceutical biopharmaceutical industry professional with significant expertise in clinical development, pharmacovigilance and benefit-risk management. His experience includes all stages of drug development, including preparation of marketing authorisation and license applications Europe and the US, as well as life cycle management activities and Medical Affairs for marketed products. Paul graduated as MD at the University of Liège, Belgium and joined the pharmaceutical industry shortly after. He spent more than 30 years in the pharmaceutical and biotech industry, working for GSK in several subsidiaries including the US and later for ThromboGenics (now Oxurion). For the last 10 years, through his own company Semaphar SRL, he has been providing services related to development strategy and benefit-risk management for various types of medicinal products and medical devices in development or on the market, predominantly to small companies in different therapeutic areas, reconciling medical expertise and regulatory requirements.